Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02483858 · ClinicalTrials.gov registry record · Phase 1
Study of Oral PQR309 in Patients With Advanced Solid Tumors
A Phase 1 study of Cancer, sponsored by PIQUR Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT02483858: Completed Phase 1 study of Cancer, sponsored by PIQUR Therapeutics.
NCT02483858 is a Phase 1 study of Cancer that has completed, run by PIQUR Therapeutics. The registered enrollment target is 70 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02483858, a Phase 1 study of Cancer, has completed, sponsored by PIQUR Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, multi-center, non-randomized, dose escalation Phase 1 study evaluating safety, tolerability, PK (pharmacokinetics) and efficacy of PQR309 in the treatment of selected patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG PQR 309
Study Locations (1)
Texas
- M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-03-21 |
| Est. Completion | 2019-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02483858
The ClinicalTrials.gov registry entry for NCT02483858 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is PIQUR Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which PQR 309 is the first listed.
NCT02483858 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02483858 about?
NCT02483858 is a clinical study titled "Study of Oral PQR309 in Patients With Advanced Solid Tumors". This is an open-label, multi-center, non-randomized, dose escalation Phase 1 study evaluating safety, tolerability, PK (pharmacokinetics) and efficacy of PQR309 in the treatment of selected patients with advanced solid tumors.
What is the current status of trial NCT02483858?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2019-03-21. Estimated completion is 2019-03-21.
What conditions does trial NCT02483858 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT02483858?
The interventions under investigation include: PQR 309 (DRUG).
Who is sponsoring clinical trial NCT02483858?
This trial is sponsored by PIQUR Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02483858 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.